Diabetes Therapy
Short-term sulfonylurea therapy is safe for diabetes caused by KCNJ11 mutations
Published in Obesity and Diabetes Week, September 18th, 2006
According to recent research from England, "Heterozygous activating mutations in KCNJ11, encoding the Kir6.2 subunit of the ATP-sensitive potassium (KATP ) channel, cause 30 to 58% of cases of diabetes diagnosed in patients under 6 months of age. Patients present with ketoacidosis or severe hyperglycemia and are treated with insulin. Diabetes results from impaired insulin secretion caused by a failure of the beta-cell KATP channel to close in response to increased intracellular ATP. Sulfonylureas close the KATP channel by an...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Obesity and Diabetes Week
More Articles from Obesity and Diabetes Week
- Adiponectin Receptor
Adiponectin receptor-1 expression increases during weight loss in obese with IGT - Obesity Complications
Obese orthopedic patients have higher postoperative complication and failure rates - Obesity Research
Characteristics of adrenomedullin make it eligible as new adipokine - Obesity Research
Research confirms the human body strongly resists attempts to lose weight - Obesity Therapy
Sitagliptin improved dipeptidyl peptidose-IV activity and glucagons-like peptide-1 in obese - Adverse Drug Reaction
Adverse responses to rosiglitazone in type 2 diabetes model can be predicted by genetics - More from this issue of Obesity and Diabetes Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
